[Asia Economy Reporter Jang Hyowon] Following the news that Withwin Investment has invested in Gyeongnam Pharmaceutical, Gyeongnam Pharmaceutical and its affiliates are all experiencing a surge.


As of 2:49 PM on the 8th, Gyeongnam Pharmaceutical, Liveplex, and Live Financial are trading at 10,050 KRW, 1,210 KRW, and 1,760 KRW respectively, up 17.58%, 28.72%, and 5.71% compared to the previous day.


According to industry sources on the 5th, Gyeongnam Pharmaceutical decided to issue private convertible bonds (CB) worth 14.5 billion KRW. The bond maturity is 3 years, with a coupon rate and maturity interest rate of 3% each.


The CB subscribers are Withwin Investment affiliates Withwin Investment Association No. 57 and Withwin Holdings, investing 6 billion KRW and 3.5 billion KRW respectively.


Recently, Gyeongnam Pharmaceutical signed export contracts for its flagship product "Lemona" with Nexus Pharma in a total of five countries: the United Kingdom, Australia, the Philippines, Cambodia, and Malaysia.


Hot Picks Today

"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ① "Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①

Additionally, together with Gyeongnam Pharmaceutical Healthcare, which has production facilities for public masks KF80 and KF94 as well as droplet masks, they plan to supply these products using domestic pharmacy and drugstore sales networks.


한글 기사 보기
This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing